Insulin Sensitivity during Combined Androgen Blockade for Prostate Cancer
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
CONTEXT: GnRH agonists markedly increase fat mass in men with prostate cancer, but little is known about the effects of treatment on insulin sensitivity. OBJECTIVE: The objective of the study was to assess the effects of short-term GnRH agonist treatment on insulin sensitivity. DESIGN: This was a prospective 12-wk study. SETTING: The study was conducted at a general clinical research center. PATIENTS OR OTHER PARTICIPANTS: We studied 25 men with locally advanced or recurrent prostate cancer, no radiographic evidence of metastases, no history of diabetes mellitus, and no evidence of diabetes mellitus at baseline visit. INTERVENTION: Leuprolide depot and bicalutamide were used in the study. MAIN OUTCOME MEASURES: Oral glucose tolerance tests and body composition assessment by dual-energy x-ray absorptiometry were performed at baseline and wk 12. The primary study outcome was change in insulin sensitivity index. RESULTS: Mean (+/- se) percentage fat body mass increased by 4.3 +/- 1.3% from baseline to wk 12 (P = 0.002). Insulin sensitivity index decreased by 12.9 +/- 7.6% (P = 0.02). Insulin sensitivity by homeostatic model assessment decreased by 12.8 +/- 5.9% (P = 0.02). Fasting plasma insulin levels increased by 25.9 +/- 9.3% (P = 0.04). Mean glycosylated hemoglobin also increased significantly (P < 0.001). CONCLUSIONS: Short-term treatment with leuprolide and bicalutamide significantly increased fat mass and decreased insulin sensitivity in men with prostate cancer. These observations suggest that GnRH agonists may increase the risk of diabetes mellitus and cardiovascular disease in older men.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 4×
“The whole-body ISI was calculated from fasting plasma insulinandglucoseconcentrationsandmeanplasmainsulinandglucose concentrations during the OGTT, with ISI 10,000/square root of (fasting plasma glucose fasting plasma insulin) (mean OGTT glucose mean OGTT insulin) ( 18 ).”
BackgroundMethodResultInfluentialDeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535 · cited 1×
“The observed increase in HDL cholesterol levels contrasts to the low levels of HDL cholesterol associated with the classic metabolic syndrome (14, 15 ).”
BackgroundPrevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999-2002
Hedley, A. A. (2004) · JAMA · doi:10.1001/jama.291.23.2847 · Cited by 4,460
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699 · cited 1×
“Insulin resistance is a common metabolic abnormality that underlies type 2 diabetes mellitus (11) and is an independentriskfactorforcardiovasculardisease( 12 ,13).Insulin resistance is also linked to a variety of abnormalities associated with cardiovascular disease risk including obesity, hypertension, elevated trigly…”
BackgroundAndrogen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083 · cited 1×
“nRH AGONISTS ARE the cornerstone of treatment for metastatic prostate cancer and a routine part of management for many men with local and local-regional disease ( 1 ).”
BackgroundFerrannini, E., Natali, A., Bell, P., Cavallo-Perin, P., Lalic, N., & Mingrone, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119628 · Cited by 898
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1992) · Medical Science Symposia Series · doi:10.1007/978-94-011-2700-4_10 · Cited by 865
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · cited 3×
“Consistent with earlier reports ( 5 , 8, 22), we observed that”
BackgroundMethodResultSelf-citation
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
“This has been studied with respect to its adverse effects on non-prostate cancer morbidity and mortality in these me”
BackgroundDiabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Self-citationHormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Self-citationHeidenreich, A., Bellmunt, J., Bolla, M., Joniau, S., Matveev, V. B., Mottet, N., Wiegel, T., & Zattoni, F. (2013) · Cited by 875
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
“9% increase in fasting plasma insulin [30].”
Self-citationGillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citationObesity and colon and rectal cancer risk: a meta-analysis of prospective studies
Larsson, S. C., & Wolk, A. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.556 · Cited by 632
“Several clinical trials have shown that testosterone therapy decreases adiposity and improves insulin sensitivity (66–69), whereas androgen deprivation increases adiposity and insulin resistance in men (70, 71).”
BackgroundKeating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp404 · Cited by 622
Self-citationTestosterone: a metabolic hormone in health and disease
Kelly, D. M., & Jones, T. H. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0455 · Cited by 577
Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning
Pollak, M. N. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0263 · Cited by 507
Low testosterone levels are common and associated with insulin resistance in men with diabetes
Grossmann, M., Thomas, M. C., Panagiotopoulos, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., & Jerums, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2177 · Cited by 468
“Men with Klinefelter syndrome have increased insulin resistance (27), and androgen deprivation therapy in men with prostate cancer increases the risk of developing the metabolic syndrome as well as that of incident diabetes (28, 29).”
BackgroundNguyen, P. L., Je, Y., Schutz, F. A. B., Hoffman, K. E., Hu, J. C., Parekh, A., Beckman, J. A., & Choueiri, T. K. (2011) · JAMA · doi:10.1001/jama.2011.1745 · Cited by 432
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., & Zakai, N. (2010) · Circulation · doi:10.1161/circulationaha.109.192695 · Cited by 383
Self-citationTestosterone deficiency, insulin resistance and the metabolic syndrome
Zitzmann, M. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.212 · Cited by 352
“Low testosterone levels are associated with insulin resistanc”
BackgroundMetabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.01.047 · Cited by 349
Self-citationHeufelder, A. E., Saad, F., Bunck, M. C., & Gooren, L. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.007005 · Cited by 349
Kalinchenko, S. Y., Tishova, Y. A., Mskhalaya, G. J., Gooren, L. J. G., Giltay, E. J., & Saad, F. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03845.x · Cited by 341
Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
Alibhai, S. M. H., Duong-Hua, M., Sutradhar, R., Fleshner, N. E., Warde, P., Cheung, A. M., & Paszat, L. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0923 · Cited by 334
Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer
Taylor, L. G., Canfield, S. E., & Du, X. L. (2009) · Cancer · doi:10.1002/cncr.24283 · Cited by 324
“A study by D’Amico et al indicated that men who were randomized to receive radiation therapy had a significantly increased risk of all-cause mortality compared with men who received radiation therapy and ADT.53 It was reported that much of this increase was in men without any comorbidity or with only minor comorbiditi…”
ResultInfluentialSadovsky, R., Basson, R., Krychman, M., Morales, A. M., Schover, L., Wang, R., & Incrocci, L. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01620.x · Cited by 310
Long-Term Treatment of Transsexuals with Cross-Sex Hormones: Extensive Personal Experience
Gooren, L. J., Giltay, E. J., & Bunck, M. C. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1809 · Cited by 308
The Dark Side of Testosterone Deficiency: I. Metabolic Syndrome and Erectile Dysfunction
Traish, A. M., Guay, A., Feeley, R., & Saad, F. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.005215 · Cited by 286
Sex Steroids and All-Cause and Cause-Specific Mortality in Men
Araujo, A. B. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.12.1252 · Cited by 272
“Findings from a recent meta-analysis(36) indicate that lower testosterone level increases risk of type 2 diabetes mellitus and that testosterone withdrawal increases insulin resistance.(37) Furthermore, data from the MMAS indicate that low testosterone level increases risk of obesity,(38) metabolic syndrome,(10) and t…”
BackgroundContemporary Role of Androgen Deprivation Therapy for Prostate Cancer
Pagliarulo, V., Bracarda, S., Eisenberger, M. A., Mottet, N., Schröder, F. H., Sternberg, C. N., & Studer, U. E. (2012) · European Urology · doi:10.1016/j.eururo.2011.08.026 · Cited by 266
“In response to ADT, patients with PCa may experience an increase in fasting insulin [93] and a decrease in insulin receptor sensitivity [94].”
Aversa, A., Bruzziches, R., Francomano, D., Rosano, G., Isidori, A. M., Lenzi, A., & Spera, G. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01931.x · Cited by 265
Efstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., & Smith, M. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3752 · Cited by 261
Self-citationThe Dark Side of Testosterone Deficiency: III. Cardiovascular Disease
Traish, A. M., Saad, F., Feeley, R. J., & Guay, A. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.007245 · Cited by 239
Metformin and Other Biguanides in Oncology: Advancing the Research Agenda
Pollak, M. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0175 · Cited by 240
Insulin receptor expression by human prostate cancers
Cox, M. E., Gleave, M. E., Zakikhani, M., Bell, R. H., Piura, E., Vickers, E., Cunningham, M., Larsson, O., Fazli, L., & Pollak, M. (2009) · The Prostate · doi:10.1002/pros.20852 · Cited by 223
“Finally, in the context of data showing that castration therapy is associated with hyperinsulinemia [40], our demonstration of insulin receptors in prostate cancer tissuesmotivates research concerning roles of insulin signalling in progression of prostate cancer to castration-resistant behavior.”
BackgroundEndocrine Aspects of Male Sexual Dysfunctions
Buvat, J., Maggi, M., Gooren, L., Guay, A. T., Kaufman, J., Morgentaler, A., Schulman, C., Tan, H. M., Torres, L. O., Yassin, A., et al. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01780.x · Cited by 221
Yialamas, M. A., Dwyer, A. A., Hanley, E., Lee, H., Pitteloud, N., & Hayes, F. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0454 · Cited by 220
Self-citationSmith, M. R., Lee, H., McGovern, F., Fallon, M. A., Goode, M., Zietman, A. L., & Finkelstein, J. S. (2008) · Cancer · doi:10.1002/cncr.23440 · Cited by 207
“Another prospective study of nondiabetic men with prostate cancer demonstrated that short-term treatment with a GnRH agonist significantly decreased insulin sensitivity and increased glycated hemoglobin.(7) Consistent with these results, a large population-based study demonstrated that GnRH agonists are asso-”
BackgroundResultSelf-citationGalvão, D. A., Spry, N., Denham, J., Taaffe, D. R., Cormie, P., Joseph, D., Lamb, D. S., Chambers, S. K., & Newton, R. U. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.041 · Cited by 198
“Men with prostate cancer (PCa) undergoing androgendeprivation therapy (ADT) are recognised to gain fat mass, lose lean mass, and be subject to a series of adverse effects from therapy [1–4].”
BackgroundHamilton, E. J., Gianatti, E., Strauss, B. J., Wentworth, J., Lim-Joon, D., Bolton, D., Zajac, J. D., & Grossmann, M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03942.x · Cited by 196
Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., Turner, D., & Newton, R. U. (2009) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2008.51 · Cited by 198
Management of Complications of Prostate Cancer Treatment
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., & Smith, M. R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0002 · Cited by 196
Self-citationEfstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., & Smith, M. R. (2008) · European Urology · doi:10.1016/j.eururo.2008.01.021 · Cited by 200
“Similarly, GnRHa treatment-related increases in serum low-density lipoprotein cholesterol and triglycerides [19,20] appears to be primarily an early adverse effect.”
BackgroundSelf-citationPothiwala, P., Jain, S. K., & Yaturu, S. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2008.0065 · Cited by 187
“73 Thus, hyperinsulinemia has been linked to neoplastic proliferation of various organ cells (Fig.”
Venkateswaran, V., Haddad, A. Q., Fleshner, N. E., Fan, R., Sugar, L. M., Nam, R., Klotz, L. H., & Pollak, M. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm231 · Cited by 182
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., Zakai, N., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20061 · Cited by 188
Self-citationAndrogen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis
Shahani, S., Braga-Basaria, M., & Basaria, S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2595 · Cited by 185
“Downloaded from jcem.endojournals.org by on January 25, 2010 baseline,againindicatingdevelopmentofinsulinresistancewith increasing adiposity ( 26 ).”
MethodInfluentialThe Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer
Iacovelli, R., Ciccarese, C., Bria, E., Romano, M., Fantinel, E., Bimbatti, D., Muraglia, A., Porcaro, A. B., Siracusano, S., Brunelli, M., et al. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.12.007 · Cited by 171
Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks
Isbarn, H., Boccon-Gibod, L., Carroll, P. R., Montorsi, F., Schulman, C., Smith, M. R., Sternberg, C. N., & Studer, U. E. (2009) · European Urology · doi:10.1016/j.eururo.2008.10.008 · Cited by 171
“In a 12-wk prospective study of nondiabetic men, ADT significantly decreased insulin sensitivity [11].”
Self-citationHypogonadism and male obesity: Focus on unresolved questions
Grossmann, M. (2018) · Clinical Endocrinology · doi:10.1111/cen.13723 · Cited by 164
Lópes, R. D., Higano, C. S., Slovin, S. F., Nelson, A. J., Bigelow, R., Sørensen, P. S., Melloni, C., Goodman, S. G., Evans, C. P., Nilsson, J. Å., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056810 · Cited by 175
MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease
Schiffer, L., Kempegowda, P., Arlt, W., & O’Reilly, M. W. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0124 · Cited by 151
Haseen, F., Murray, L., Cardwell, C. R., O’Sullivan, J. M., & Cantwell, M. M. (2010) · Journal of Cancer Survivorship · doi:10.1007/s11764-009-0114-1 · Cited by 180
“Six studies [17, 22, 26-28, 30], involving 260 patients and with treatment periods ranging from 3 to 24 months, reported the % change in percentage of lean mass (Table 2).”
BackgroundInfluentialExercise in Prevention and Management of Cancer
Newton, R. U., & Galvao, D. A. (2008) · Current Treatment Options in Oncology · doi:10.1007/s11864-008-0065-1 · Cited by 182
Androgen deprivation therapy for prostate cancer: new concepts and concerns
Smith, M. R. (2007) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32814db88c · Cited by 157
Self-citationHe, X., Tu, S., Lee, M., & Yeung, S. J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr020 · Cited by 161
“Moreover, many prostate cancer patients who are receiving short-term [50] or long-term androgen-deprivation therapy [51] are at risk for developing insulin resistance and hyperglycemia (i.”
BackgroundJespersen, C. G., Nørgaard, M., & Borre, M. (2013) · European Urology · doi:10.1016/j.eururo.2013.02.002 · Cited by 159
“These findings are in line with the results of other recent studies [7–12], and the association appears biologically plausible due to development of metabolic syndrome, which predisposes to development of thrombosis [3–6].”
BackgroundResultMetabolic Disorders and Male Hypogonadotropic Hypogonadism
Pivonello, R., Menafra, D., Riccio, E., Garifalos, F., Mazzella, M., de Angelis, C., & Colao, A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00345 · Cited by 143
“ADT-induced Hypo-H in men with prostate cancer has been associated with increased fat mass (45–47), decreased insulin sensitivity (45, 48), and increased risk of MetS and T2-DM (49).”
BackgroundMetabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2013) · Journal of Urology · doi:10.1016/j.juro.2012.11.017 · Cited by 137
Self-citationAdverse effects of androgen‐deprivation therapy in prostate cancer and their management
Rhee, H., Gunter, J. H., Heathcote, P. S., Ho, K. K. Y., Stricker, P. D., Corcoran, N. M., & Nelson, C. C. (2014) · British Journal of Urology · doi:10.1111/bju.12964 · Cited by 147
Nobes, J. P., Langley, S. E. M., Klopper, T., Russell-Jones, D. L., & Laing, R. W. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10555.x · Cited by 132
Rothermundt, C. A., Hayoz, S., Templeton, A. J., Winterhalder, R., Strebel, R. T., Bärtschi, D., Pollak, M., Lui, L., Endt, K., Schiess, R., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.12.057 · Cited by 128
“Article info Article history: Accepted December 23, 2013 Published online ahead of print on January 4, 2014 Keywords: Castration-resistant prostate cancer Metabolic parameters Metformin Background: There is evidence linking metformin to improved prostate cancer (PCa)-related outcomes.”
BackgroundInfluentialKintzel, P. E., Chase, S. L., Schultz, L. M., & O’Rourke, T. J. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.12.1511 · Cited by 135
“001) were documented 3 months after initiation of ADT in 25 nondiabetic men with locally advanced or recurrent prostate cancer.(23) Insulin sensitivity gauged with use of the homeostatic model decreased 12.”
BackgroundMorán, Ó., Galietta, L. J. V., & Zegarra‐Moran, O. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4422-3 · Cited by 126
Basaria, S. (2008) · Journal of Andrology · doi:10.2164/jandrol.108.005454 · Cited by 119
Smith, M. R., Lee, H., Fallon, M. A., & Nathan, D. M. (2008) · Urology · doi:10.1016/j.urology.2007.08.035 · Cited by 133
Self-citationSmith, M. R., Malkowicz, S. B., Chu, F., Forrest, J., Price, D., Sieber, P., Barnette, K. G., Rodriguez, D., & Steiner, M. S. (2008) · Journal of Urology · doi:10.1016/j.juro.2007.08.137 · Cited by 117
Self-citationInsulin Increases De Novo Steroidogenesis in Prostate Cancer Cells
Lubik, A. A., Gunter, J. H., Hendy, S. C., Locke, J. A., Adomat, H. H., Thompson, V., Herington, A., Gleave, M. E., Pollak, M., & Nelson, C. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2470 · Cited by 116
“Recent studies have specifically identified a correlation between elevated C-peptide levels, a surrogate measure of insulin levels, with high-grade prostate cancer and worse patient prognosis (6, 7, 24, 26, 27).”
BackgroundThe Relationship between Testosterone Deficiency and Men's Health
Tsujimura, A. (2013) · The World Journal of Men s Health · doi:10.5534/wjmh.2013.31.2.126 · Cited by 143
“At present, it is well accepted that a low serum testosterone level has emerged as a reliable prognosticator of MS in men whose testosterone deficiency is genetic or iatrogenic following surgery,(67,74,75) or pharmacologically induced by gonadotropin-releasing hormone during prostate cancer treatment.(76)”
BackgroundHigano, C. S. (2008) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0995 · Cited by 113
“) Philadelphia: WB Saunders Company 52 Smith MR et al. (2001) Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer 91: 2238–2245 53 Planas J et al. (2007) The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int 99: 812–816 54 Kanis JA et al.…”
BackgroundInfluentialGrossmann, M., Hamilton, E. J., Gilfillan, C., Bolton, D., Joon, D. L., & Zajac, J. D. (2011) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb02979.x · Cited by 104
Hu, J. C., Williams, S. B., O’Malley, A. J., Smith, M. R., Nguyen, P. L., & Keating, N. L. (2012) · European Urology · doi:10.1016/j.eururo.2012.01.045 · Cited by 113
“Although the exact mechanism by which GnRH agonists affect central and peripheral arteries remains unknown, they are known to increase fat mass, increase fasting insulin levels, decrease insulin sensitivity, and alter serum lipoproteins, which may lead to increased arterial stiffness and atherosclerosis [10,23–26].”
BackgroundSelf-citationShabsigh, R., Arver, S., Channer, K. S., Eardley, I., Fabbri, A., Gooren, L., Heufelder, A., Jones, H., Meryn, S., & Zitzmann, M. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01696.x · Cited by 106
Greco, E. A., Spera, G., & Aversa, A. (2006) · European Urology · doi:10.1016/j.eururo.2006.06.049 · Cited by 109
“Also, recent evidences demonstrated that androgen deprivation for prostate cancer might alter insulin sensitivity, thus suggesting a potential role in the development of insulin resistance [48].”
BackgroundTestosterone and glucose metabolism in men: current concepts and controversies
Grossmann, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0393 · Cited by 100
“1 nmol/l) induced by androgen deprivation therapy consistently induces insulin resistance (Smith et al .”
BackgroundDerweesh, I. H., DiBlasio, C. J., Kincade, M. C., Malcolm, J. B., Lamar, K. D., Patterson, A. L., Kitabchi, A. E., & Wake, R. W. (2007) · BJU International · doi:10.1111/j.1464-410x.2007.07184.x · Cited by 104
Saylor, P. J., & Smith, M. R. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0014 · Cited by 107
Self-citationThe role of testosterone in the metabolic syndrome: A review
Saad, F., & Gooren, L. J. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.12.022 · Cited by 111
Metformin and Prostate Cancer: a New Role for an Old Drug
Whitburn, J., Edwards, C. M., & Sooriakumaran, P. (2017) · Current Urology Reports · doi:10.1007/s11934-017-0693-8 · Cited by 98
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer
Faris, J. E., & Smith, M. R. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283391fd1 · Cited by 97
Self-citationObesity and mortality in men with locally advanced prostate cancer: Analysis of RTOG 85‐31
Efstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., & Smith, M. R. (2007) · Cancer · doi:10.1002/cncr.23093 · Cited by 99
Self-citationAndrogen regulation of prostate cancer: Where are we now?
Corona, G., Baldi, E., & Maggi, M. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03347072 · Cited by 108
Why does COVID‐19 kill more elderly men than women? Is there a role for testosterone?
Papadopoulos, V., Li, L., & Samplaski, M. K. (2020) · Andrology · doi:10.1111/andr.12868 · Cited by 104
“However, a series of studies showed that androgen deprivation in prostate cancer patients induces components of the metabolic syndrome (28-30) and administration of T to hypogonadal men improves insulin resistance, obesity and dyslipidemia (23, 31).”
BackgroundDiabetes and mortality in patients with prostate cancer: a meta-analysis
Lee, J., Giovannucci, E. L., & Jeon, J. Y. (2016) · SpringerPlus · doi:10.1186/s40064-016-3233-y · Cited by 96
“In this respect, long-term androgen deprivation therapy, which is commonly used to treat patients with prostate cancer, increases insulin resistance and hyperglycemia, which in turn induces cardiovascular diseases (Basaria et al. 2006; Smith et al. 2006).”
BackgroundLangley, R. E., Cafferty, F. H., Alhasso, A. A., Rosen, S. D., Sundaram, S. K., Freeman, S. C., Pollock, P., Jinks, R. C., Godsland, I. F., Kockelbergh, R. C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70025-1 · Cited by 96
Aversa, A., Bruzziches, R., Francomano, D., Spera, G., & Lenzi, A. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03350341 · Cited by 99
Androgens and prostate cancer; pathogenesis and deprivation therapy
Grossmann, M., Cheung, A. S., & Zajac, J. D. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.001 · Cited by 97
Western-style diet, sex steroids and metabolism
Varlamov, O. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.05.025 · Cited by 102
“ADT-related metabolic changes include the early onset of sarcopenic obesity [94] and insulin resistance [95-97], while longer duration of ADT is associated with diabetes [90, 98], and dyslipidemia [99, 100].”
BackgroundMechanisms underlying the metabolic actions of testosterone in humans: A narrative review
Dandona, P., Dhindsa, S., Ghanim, H., & Saad, F. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14206 · Cited by 95
“These effects of ADT bring forth the consistency in metabolic actions of testosterone in various clinical scenarios: (a) the gradual decline of testosterone in obesity and ageing, (b) the treatment of hypogonadism and (c) the precipitous and dramatic loss of testosterone after ADT.”
BackgroundInfluentialLage, M. J., Barber, B., & Markus, R. A. (2007) · Urology · doi:10.1016/j.urology.2007.08.012 · Cited by 89
Androgen deprivation and thromboembolic events in men with prostate cancer
Ehdaie, B., Atoria, C. L., Gupta, A., Feifer, A. H., Lowrance, W. T., Morris, M. J., Scardino, P. T., Eastham, J. A., & Elkin, E. B. (2011) · Cancer · doi:10.1002/cncr.26623 · Cited by 89
Androgen deficiency and atherosclerosis: The lipid link
Traish, A. M., Abdou, R. Y., & Kypreos, K. E. (2009) · Vascular Pharmacology · doi:10.1016/j.vph.2009.09.003 · Cited by 89
Walker, L. M., Tran, S., & Robinson, J. W. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.05.004 · Cited by 86
Metabolic changes in patients with prostate cancer during androgen deprivation therapy
Mitsuzuka, K., & Arai, Y. (2017) · International Journal of Urology · doi:10.1111/iju.13473 · Cited by 85
WALL, B. A., GALVãO, D. A., FATEHEE, N., TAAFFE, D. R., SPRY, N., JOSEPH, D., HEBERT, J. J., & NEWTON, R. U. (2017) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001277 · Cited by 81
Haider, A., Gooren, L. J. G., Padungtod, P., & Saad, F. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1202774 · Cited by 83
Padhi, D., Higano, C. S., Shore, N. D., Sieber, P., Rasmussen, E., & Smith, M. R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1271 · Cited by 81
Self-citationThe prevalence of and risk factors for androgen deficiency in aging Taiwanese men
Liu, C.-C., Wu, W.-J., Lee, Y.-C., Wang, C.-J., Ke, H.-L., Li, W.-M., Hsiao, H.-L., Yeh, H.-C., Li, C.-C., Chou, Y.-H., et al. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.01171.x · Cited by 82
Saad, F., & Gooren, L. J. (2011) · Journal of Obesity · doi:10.1155/2011/471584 · Cited by 82
“androgen ablation therapy [22, 67], particularly in the longer-term [68].”
BackgroundNew considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists
Shore, N. D., Abrahamsson, P.-A., Anderson, J., Crawford, E. D., & Lange, P. (2012) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2012.25 · Cited by 85
Metformin in prostate cancer: two for the price of one
Clements, A., Gao, B., Yeap, S. H., Wong, M. K., Ali, S. S., & Gurney, H. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr037 · Cited by 84
“Studies have showed that even shortterm (12 weeks) use of ADT significantly increased fat mass and decreased insulin sensitivity in men with prostate cancer [13].”
BackgroundYu, I.-C., Lin, H.-Y., Liu, N.-C., Sparks, J. D., Yeh, S., Fang, L.-Y., Chen, L., & Chang, C. (2013) · Diabetes · doi:10.2337/db12-0135 · Cited by 79
“The accumulation of visceral adiposity during a short-term ADT period is associated with increasing insulin levels, which may be an initiating event leading to metabolic dysregulation (5).”
BackgroundSalonen, A. J., Taari, K., Ala‐Opas, M., Viitanen, J., Lundstedt, S., & Tammela, T. L. J. (2012) · European Urology · doi:10.1016/j.eururo.2012.07.040 · Cited by 84
“body mass, serum lipoproteins, insulin sensitivity, and obesity [18–20], thus raising the odds of CVmorbidity by up to 20% [21].”
BackgroundCholesterol and male fertility: What about orphans and adopted?
Maqdasy, S., Baptissart, M., Vega, A., Baron, S., Lobaccaro, J. A., & Volle, D. H. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.011 · Cited by 92
“On the other side, altered testicular functions may increase the risk of metabolic syndrome (Kupelian et al., 2006; Smith et al., 2006).”
Background
Metadata
- Authors
- Smith, M. R., Lee, H., & Nathan, D. M.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Smith, Matthew R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-04
- Volume
- 91
- Issue
- 4
- Pages
- 1305-1308
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2129509910
- Cited by
- 493
- References
- 25
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 14 · 2023: 12 · 2022: 13 · 2021: 9 · 2020: 14 · 2019: 15 · 2018: 20 · 2017: 25 · 2016: 24 · 2015: 26 · 2014: 26 · 2013: 35 · 2012: 46
- FWCI
- 32.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Prostate Cancer Foundation
- Massachusetts General Hospital
- National Institutes of Health
- National Cancer Institute (P50 CA 90381, P50CA090381)
- National Center for Research Resources (M01RR001066, M01-RR01066)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- insulin sensitivity, prostate cancer, combined androgen blockade, GnRH agonist, leuprolide, bicalutamide, fat mass, insulin resistance, diabetes risk, cardiovascular risk, fasting insulin, HbA1c
- MeSH terms
- Adipose Tissue, Adult, Androgen Antagonists, Anthropometry, Blood Glucose, Body Composition, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Gonadotropin-Releasing Hormone, Lipids, Male, Prospective Studies, Prostatic Neoplasms, Testosterone, Biomarkers, Absorptiometry, Photon, Treatment Outcome, Antineoplastic Agents, Hormonal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.